Patient characteristics and treatments one year after diagnosis of renal cancer in 2015 according to the presence or absence of metastasis and a history of another tumour: A national observational study.

This study describes the characteristics, management and outcome of patients one year after a diagnosis of renal cancer, according to the presence of a history of another tumour and metastases at diagnosis or during the first year.

Based on information from the national health data system (SNDS), 10,989 general scheme beneficiaries (>15 years) with a first hospital stay in 2015 for renal cancer were divided into groups according to the presence of a history of another tumour or metastases.

In this cohort of 10,989 people (75 years and older: 30%, men: 65%), 12% had a history of another tumour diagnosed during the two years before and 22% presented one or more metastases at the time of the index hospitalisation or during the following year. Overall, nephrectomy was performed in 56% of cases (partial nephrectomy in 29% of cases), in 63% and 36% of cases without metastases and in 68% and 40% of cases without metastases and with no history of another tumour. Overall, 2% of patients received at least one monoclonal antibody and 15% received a protein kinase inhibitor. These drugs were used in 6% and 53% of cases, respectively, in the presence of metastases and in 7% and 31% of cases, respectively, in the presence of metastases and a history of another tumour.

This study highlights the high rate of a history of another tumour and adaptation of treatment according to a history of cancer and the presence of metastases.

Bulletin du cancer. 2019 May 06 [Epub ahead of print]

Philippe Tuppin, Michel Paita, Christelle Gastaldi-Menager, Christine Le Bihan-Benjamin, Philippe Jean Bousquet, Anne Fagot Campagna

Caisse nationale d'assurance maladie (CNAM), 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France. Electronic address: ., Caisse nationale d'assurance maladie (CNAM), 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France., Institut national du cancer, 52, avenue André-Morizet, 92100 Boulogne-Billancourt, France.